Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Merger or Acquisition (September 2019)
17 slides from Bactiguard Holding Ab's merger presentation, Sep 27, 2019
Slide 1: Bactiguard enters global license agreement with Zimmer Biomet
Bactiguard enters global license agreement with Zimmer Biomet 27 September 2019 Christian Kinch, Chief Executive Officer Cecilia Edström, CFO and Deputy CEO
Slide 2: Global license agreement with Zimmer Biomet
Global license agreement with Zimmer Biomet Highlights • Exclusive global license agreement for orthopedic trauma implants • Up-front license fee of USD 3 million at signing • USD 2 million in milestone payments, contingent on U.S. regulatory clearance • Royalties on net sales following commercializ
Slide 3: Why partner with Zimmer Biomet?
Why partner with Zimmer Biomet? • A major, global player in orthopedics • Strong market position in the Americas, Europe, MEA and Asia Pacific • Revenues of USD 7.9 billion in 2018 • Broad range of products • 90-year heritage of proven clinical performance • Strategy of addressing unmet clinical nee
Slide 4: Orthopedic market segments
Orthopedic market segments Total market USD 51 billion, whereof trauma USD 7 billion and above average growth Product Segment Performance: 2018 vs. 2017 ($Millions) 2018 Orthopaedic Product Sales by Market Segment Segment 2018 2017 % change Other; 10% Joint Replacement $18,919.7 $18,242.7 3,7% Spine
Slide 5: Three major players in orthopedics
Three major players in orthopedics Revenues and market shares % of Market Share 2018 DePuy Synthes; 17% Companies 2018 2017 % change DePuy Synthes $8,827.4 $8,987.9 -1,8% Zimmer Biomet $7,081.7 $6,964.4 1,7% All Others; 35% Stryker $7,029.2 $6,608.7 6,4% Smith & Nephew $3,456.6 $3,353.4 3,1% Zimmer
Slide 6: Business model
Business model Two lines of business License agreements for various applications with Bactiguard Proprietary product portfolio – sold through distributors technology 6
Slide 7: Licensing business
Licensing business BD (C.R. Bard) • Successful partnership since 1995 • Bactiguard coated Foley catheters for the US, Japan and UK/Ireland • Generating stable annual revenues Vigilenz Medical Devices • Bactiguard coated orthopedic trauma implants for the ASEAN markets • CE mark awarded in December 2
Slide 8: Development project for vascular stents
Development project for vascular stents • To reduce the risk of thrombosis in connection with interventions in Stents save lives the bloodstream • Stents are used when blood vessels in the heart or • Project led by Professor Staffan Holmin and his research group at the nervous system need to be wide
Slide 9: The technology
The technology The galvanic effect – effective and safe • When in contact with fluids the noble metals create Gold Au a galvanic effect Silver Ag • The different electro potentials of the metals create Palladium Pd a micro current • Prevents microbial adhesion (gram positive/negative bacteria and fu
Slide 10: IP protection
IP protection ”The holy trinity” Patent* Trade Know-how secret *Current patent (2nd generation) valid until 2027/2029, 3rd generation filed 10
Slide 11: Bactiguard coated products
Bactiguard coated products BIP Foley Catheters BIP ETT, ETT Evac BIP CVC Bardex I.C/LubriSil I.C OrthoSynTM Manufacturer Bactiguard AB Bactiguard AB Bactiguard AB BD (BARD) Vigilenz Regulatory CE CE CE FDA CE approval Duration of Permanent Prolonged Prolonged Prolonged Permanent contact Claims Reduc
Slide 12: Clinical evidence
Clinical evidence • >170 million Bactiguard coated catheters used since 1995 • No adverse events associated with the coating have been reported • > 40 clinical studies (of which 31 are published) including over 100,000 patients • 35% weighted average reduction of symptomatic CAUTI in clinical studie
Slide 13: Benefits of a non-toxic, stable technology
Benefits of a non-toxic, stable technology Infection prevention Long-term Easier Multiple Safe and Low risk effect Biocompatible regulatory applications Effective path 13
Slide 14: Growth strategy
Growth strategy Value Broaden portfolio • Develop new license applications Licensing • Expand BIP portfolio • 1-2 new deals per year • CE mark for trauma implants important reference BIP portfolio • Increase in-market penetration • Strengthen clinical evidence • Add new markets in EU Time 14
Slide 15: Financial targets
Financial targets • Average sales growth of 20% per annum for a 5-year period, with 2015 as the base year – starting point MSEK 118.5 • EBITDA margin of at least 30% at the end of the 5-year period (by 2020) • Equity ratio of at least 30% • Over time uphold a dividend policy of 30-50% of net profit,
Slide 16: Concluding remarks
Concluding remarks • Important milestone for Bactiguard • Zimmer Biomet a major, global player in orthopedics • Confirms the value of the Bactiguard technology in a new application and global context • Up-front license fee of USD 3 million at signing • USD 2 million in additional payments contingent
Slide 17: More information available at www.bactiguard.se
More information available at www.bactiguard.se For questions and additional information, please contact: Christian Kinch CEO Switchboard +46 8 440 58 80 christian.kinch@bactiguard.se @ChristianKinch Cecilia Edström CFO and Deputy CEO Cell phone +46 72 226 23 28 cecilia.edstrom@bactiguard.se @Edstro
Bactiguard Holding — Merger or Acquisition (September 2019) on 6ix